A phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumours
Nicola Steele(Cancer Research UK Scotland Institute), Johann S. de Bono(Royal Marsden NHS Foundation Trust), J A Evans(Cancer Research UK Scotland Institute), Laura Vidal(Vall d'Hebron Hospital Universitari), Robert Brown(Emerson College), Gerhardt Attard(London Cancer), P. Buhl-Jensen(Cancer Research UK Scotland Institute), Sarah P. Blagden(Churchill Hospital), JA Plumb(Cancer Research UK Scotland Institute), Anne Rasmussen(Stiftung Wissenschaft und Politik, German Institute for International and Security Affairs)
Cited by 19
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k